Ancilia Biosciences: Funding, Investors & Team (Sep 2026)
Ancilia Biosciences develops engineered bacterial therapies to treat diseases linked to the microbiome. It provides and develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications.
Ancilia Biosciences has raised $11.1M across 2 funding rounds on record, the most recent an undisclosed round of $10.1M announced in Apr 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ancilia Biosciences Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Ancilia Biosciences Funding Rounds
Ancilia Biosciences raised $1.0M in an undisclosed round announced in May 2023.
2.9 years later, an undisclosed round of $10.1M was announced in Apr 2026.
Ancilia Biosciences Founders and Leadership Team
No contact details are on record for this team yet.
Ancilia Biosciences Funding Compared to Other Biotechnology Startups
Ancilia Biosciences' latest round of $10.1M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ancilia Biosciences in Biotechnology and New York
Companies Similar to Ancilia Biosciences
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Ancilia Biosciences Funding FAQs
What does Ancilia Biosciences do?
Ancilia Biosciences develops engineered bacterial therapies to treat diseases linked to the microbiome. It provides and develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications.
How much funding has Ancilia Biosciences raised?
Ancilia Biosciences has raised $11.1M across 2 rounds on record. The most recent is an undisclosed round of $10.1M announced in Apr 2026.
When did Ancilia Biosciences last raise funding?
Ancilia Biosciences' most recent funding round on record is an undisclosed round of $10.1M, announced in Apr 2026.
Who is the CEO of Ancilia Biosciences?
Alexandra Sakatos is listed as CEO at Ancilia Biosciences.
Where is Ancilia Biosciences headquartered?
Ancilia Biosciences is based in New York, United States.
How many employees does Ancilia Biosciences have?
Ancilia Biosciences is in the 1-10 employee band.
How does Ancilia Biosciences' funding compare to other Biotechnology startups?
Ancilia Biosciences' latest round of $10.1M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Ancilia Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ancilia Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.